Company
Company
No. 9847 of 75986top 13%down 2136 places this week
3 direct links
In a group of 1534 closely linked entities, around
Weighted by public relations with evidence, recomputed daily.
Arrows show the direction of the relationship. Filter to focus on a business area.
Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreementView source
10 of which are being or have been conducted in China by AkesoView source
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationallyView source
dependence on the effectiveness of Akeso's patents and other protections for innovative productsView source
Showing 1 to 4 of 4
Read the assertion alongside its sources. Expand a row to inspect the evidence.
dependence on the effectiveness of Akeso's patents and other protections for innovative products
PR Newswire news releases · 2026-10-25 23:31
dependence on the effectiveness of Akeso's patents and other protections for innovative productsView source
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally
PR Newswire news releases · 2026-10-25 23:31
the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationallyView source
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.View source
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.View source
Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs.
PR Newswire news releases · 2026-10-25 23:31
Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs.View source
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.
PR Newswire news releases · 2026-10-25 23:31
Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.View source
Showing 1 to 6 of 16
Valuation data is available on Pro and Research.
Included in ProKnow a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.
Not available: Company signals · Financials · Filings · Sites · Guidance